Caffarelli Carlo, Giannetti Arianna, Giannì Giuliana, Ricci Giampaolo
Clinica Pediatrica, Azienda Ospedaliero-Universitaria, Department of Medicine and Surgery, Università di Parma, Parma, Italy.
Paediatrics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Front Med (Lausanne). 2023 Aug 16;10:1214963. doi: 10.3389/fmed.2023.1214963. eCollection 2023.
Atopic dermatitis (AD) is a chronic inflammatory disease with a heterogeneous pathogenesis correlated with dysregulation of the immune system and a prevalence of the T2-mediated immune pathway. Recent understanding of the pathogenesis of AD has allowed the development of new drugs targeting different mechanisms and cytokines that have changed the treatment approach. The aim of this review is to update knowledge on the standard of care and recent advancements in the control of skin inflammation. In light of recent guidelines, we report on the clinical efficacy of novel treatments, with special attention to situations where biologics and small molecules are involved.
特应性皮炎（AD）是一种慢性炎症性疾病，其发病机制异质性，与免疫系统失调以及T2介导的免疫途径的普遍存在相关。对AD发病机制的最新认识使得能够开发针对不同机制和细胞因子的新药，从而改变了治疗方法。本综述的目的是更新关于皮肤炎症控制的护理标准和最新进展的知识。根据最近的指南，我们报告了新型治疗方法的临床疗效，特别关注涉及生物制剂和小分子的情况。
